Sequencing trastuzumab deruxtecan and sacituzumab govitecan in metastatic breast cancer: a systematic review and meta-analysis
European Journal of Clinical Pharmacology · 2026-12 · 82 (12)
DOI: 10.1007/s00228-026-04218-0 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift European Journal of Clinical Pharmacology, online erschienen am 09.11.2026. Verfasst von Antonios Katsarolis und 4 weiteren Autor:innen. Beteiligte Einrichtung: School of Medicine, Aristotle University of Thessaloniki, Thessaloniki, Greece. akatsarol@auth.gr. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Humanized, Antineoplastic Agents, Immunological, Antineoplastic Combined Chemotherapy Protocols, Breast Neoplasms. Die Arbeit nennt 46 Literaturangaben.
Abstract (Originalsprache)
PURPOSE: Trastuzumab deruxtecan (T-DXd) and sacituzumab govitecan (SG) are both approved for metastatic breast cancer (mBC), and patients with HER2-low disease are often candidates for both, but the optimal sequence is undefined. This systematic review and meta-analysis compared outcomes of the second antibody-drug conjugate (ADC) by treatment sequence (SG→T-DXd versus T-DXd→SG). METHODS: Following PRISMA (PROSPERO CRD420251250322), PubMed/MEDLINE, Scopus, Cochrane CENTRAL and major oncology conference proceedings were searched through December 2025 for studies of sequential T-DXd and SG in mBC. The primary endpoint was progression-free survival on the second ADC (PFS2). Hazard ratios (HRs) were obtained from patient-level data, published estimates or reconstructed Kaplan-Meier curves and pooled using a random-effects model. Study heterogeneity was assessed using the I² statistic. Risk of bias and certainty of evidence were assessed with ROBINS-I and GRADE. RESULTS: Of 694 records, 17 retrospective studies were included; seven (292 SG→T-DXd and 286 T-DXd→SG patients) contributed to the PFS2 meta-analysis. The pooled HR for T-DXd→SG versus SG→T-DXd was 1.54 (95% CI 0.98-2.40; I²=61%), 1.72 (95% CI 1.23-2.41; I²=10%) after excluding one study, and 1.36 (95% CI 0.89-2.10) with covariate-adjusted estimates. Median PFS2 was 3.3 months with SG→T-DXd and 2.8 months with T-DXd→SG. CONCLUSION: Point estimates favoured SG→T-DXd, but given very low certainty and likely confounding by tumour subtype, current data do not establish the superiority of either sequence. Prospective, subtype-stratified studies are needed.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- School of Medicine, Aristotle University of Thessaloniki, Thessaloniki, Greece. akatsarol@auth.gr.
- Section of Medical Oncology, Second Department of Internal Medicine, Attikon University Hospital, National and Kapodistrian University of Athens, Athens, Greece.
- 2nd Department of Pathology, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece.
- Department of Medical Oncology, St Luke's Clinic, Thessaloniki, Greece.
ORCID-Profile: Antonios Katsarolis
Zitieren
APA
Katsarolis, A., Anastasiou, M., Pouliakis, A., Psyrri, A., & Fountzilas, E. (2026). Sequencing trastuzumab deruxtecan and sacituzumab govitecan in metastatic breast cancer: a systematic review and meta-analysis. European Journal of Clinical Pharmacology, 82(12). https://doi.org/10.1007/s00228-026-04218-0
Vancouver
Katsarolis A, Anastasiou M, Pouliakis A, Psyrri A, Fountzilas E. Sequencing trastuzumab deruxtecan and sacituzumab govitecan in metastatic breast cancer: a systematic review and meta-analysis. European Journal of Clinical Pharmacology. 2026;82(12). doi:10.1007/s00228-026-04218-0
BibTeX
@article{Katsarolis2026,
author = {Katsarolis, Antonios and Anastasiou, Maria and Pouliakis, Abraham and Psyrri, Amanda and Fountzilas, Elena},
title = {Sequencing trastuzumab deruxtecan and sacituzumab govitecan in metastatic breast cancer: a systematic review and meta-analysis},
journal = {European Journal of Clinical Pharmacology},
year = {2026},
volume = {82},
number = {12},
doi = {10.1007/s00228-026-04218-0}
}
EUVIMED